BiologicalDrug

Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 clinical trials

studies test it: 3
open now: 0
in phase 3: 0
first study started: 2004

How each study uses Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

Studies by the year they started

3 studies that test it; most in 2004 (2)

Studies that test Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1, by start year
Year	Studies
2004	2
2013	1

By phase

A phase 1/2 study counts in both.

Phase 1: 3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Celiac Disease: 1
Paraparesis, Tropical Spastic: 1
Leukemia, Large Granular Lymphocytic: 1

Who runs them

Industry 0 · Other 3

National Cancer Institute (NCI) (2) · National Institute of Neurological Disorders and Stroke (NINDS) (1)

Studies

Open first, then newest update. How each study uses Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.